IRIS UniCatt

Orlandi, Armando
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.578
AS - Asia 3.644
EU - Europa 2.821
SA - Sud America 837
AF - Africa 136
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 5
Totale 12.031
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.420
SG - Singapore 1.513
BR - Brasile 692
CN - Cina 650
VN - Vietnam 632
DE - Germania 628
IT - Italia 543
SE - Svezia 456
FR - Francia 272
IN - India 185
GB - Regno Unito 158
BD - Bangladesh 140
PL - Polonia 134
FI - Finlandia 131
IE - Irlanda 131
ID - Indonesia 102
HK - Hong Kong 96
JP - Giappone 85
RU - Federazione Russa 80
CA - Canada 72
AR - Argentina 67
MX - Messico 59
UA - Ucraina 59
ES - Italia 41
TR - Turchia 41
CI - Costa d'Avorio 38
NL - Olanda 38
ZA - Sudafrica 33
IQ - Iraq 32
AT - Austria 30
KR - Corea 29
EC - Ecuador 26
BE - Belgio 20
IR - Iran 20
CO - Colombia 19
SA - Arabia Saudita 18
MA - Marocco 17
LT - Lituania 16
PK - Pakistan 15
RO - Romania 14
CH - Svizzera 11
CZ - Repubblica Ceca 11
PH - Filippine 11
UZ - Uzbekistan 10
VE - Venezuela 10
CL - Cile 9
TN - Tunisia 9
AU - Australia 8
EG - Egitto 8
MY - Malesia 8
NP - Nepal 8
RS - Serbia 8
IL - Israele 7
KE - Kenya 7
JM - Giamaica 6
LB - Libano 6
LU - Lussemburgo 6
DZ - Algeria 5
HU - Ungheria 5
JO - Giordania 5
KZ - Kazakistan 5
PY - Paraguay 5
SN - Senegal 5
AZ - Azerbaigian 4
BG - Bulgaria 4
BO - Bolivia 4
CR - Costa Rica 4
HN - Honduras 4
NO - Norvegia 4
TH - Thailandia 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
ET - Etiopia 3
GE - Georgia 3
LV - Lettonia 3
PE - Perù 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
BY - Bielorussia 2
CG - Congo 2
EU - Europa 2
GA - Gabon 2
GR - Grecia 2
GT - Guatemala 2
KW - Kuwait 2
MU - Mauritius 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
OM - Oman 2
PT - Portogallo 2
SV - El Salvador 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CD - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
DM - Dominica 1
Totale 12.015
Salva come PNG Salva come JPEG
Città #
Singapore 855
San Jose 494
Chandler 487
Ashburn 470
Ho Chi Minh City 200
Hanoi 168
New York 157
Beijing 141
Chicago 130
Los Angeles 130
Dublin 123
Rome 123
Warsaw 122
Council Bluffs 110
Lauterbourg 101
Munich 95
Hyderabad 89
Hefei 87
The Dalles 80
Fairfield 78
Hong Kong 78
Houston 76
Tokyo 75
Jakarta 74
Milan 74
Wilmington 73
São Paulo 72
Frankfurt am Main 65
San Mateo 64
Boston 55
Helsinki 50
Ann Arbor 48
Princeton 47
Woodbridge 47
Turku 46
Moscow 43
Nanjing 40
London 39
Abidjan 38
Seattle 38
Buffalo 37
Dallas 36
Cattolica 34
Jacksonville 34
Cambridge 33
Orem 33
Santa Clara 31
Da Nang 30
St Louis 30
Dearborn 29
Paris 29
Haiphong 28
Kent 28
Redwood City 28
Marseille 26
Nuremberg 26
Seoul 26
Toronto 26
Chennai 25
Izmir 22
Lappeenranta 22
Nürnberg 21
Phoenix 21
Salt Lake City 21
Boardman 20
Montreal 20
Mexico City 19
Bari 18
Brooklyn 18
Brussels 18
Düsseldorf 18
Rio de Janeiro 18
Bremen 16
Dhaka 16
Poplar 16
Stockholm 16
Tampa 16
Denver 15
Johannesburg 15
Manchester 15
Tukwila 15
Amsterdam 14
Biên Hòa 14
Nanchang 14
Porto Alegre 14
Can Tho 13
Elk Grove Village 13
Guangzhou 13
Hangzhou 13
Lancaster 13
San Francisco 13
Genoa 12
Lawrence 12
Madrid 12
Querétaro 12
Salvador 12
Shanghai 12
Vienna 12
Baghdad 11
Curitiba 11
Totale 6.587
Salva come PNG Salva come JPEG
Nome #
Neoadjuvant chemotherapy in breast cancer: An advanced personalized multidisciplinary prehabilitation model (apmp-m) to optimize outcomes 333
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? 307
Diagnosis and management of breast lymphoma: A single-institution retrospective analysis 279
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients 236
Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis 227
Diagnosis and treatment of bone metastases in breast cancer: Radiotherapy, local approach and systemic therapy in a guide for clinicians 225
Development of a digital research assistant for the management of patients’ enrollment in oncology clinical trials within a research hospital 199
Mastectomy in precision oncology era: Myth or reality? 192
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 185
Trastuzumab-induced corneal ulceration: successful no-drug treatment of a "blind" side effect in a case report 182
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis 172
Level II Oncoplastic Surgery as an Alternative Option to Mastectomy with Immediate Breast Reconstruction in the Neoadjuvant Setting: A Multidisciplinary Single Center Experience 167
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 166
KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study 162
Development of a digital research assistant for the management of patients’ enrollment in oncology clinical trials within a research hospital 160
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases 158
Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer: Preliminary experience with clinically node negative patients after systemic treatment 156
Immediate prosthetic breast reconstruction after nipple-sparing mastectomy: Traditional subpectoral technique versus direct-to-implant prepectoral reconstruction without acellular dermal matrix 156
Clinical, pathological and prognostic features of rare braf mutations in metastatic colorectal cancer (Mcrc): A bi-institutional retrospective analysis (rebus study) 156
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients 155
AMAROS Study: Overall Survival in Breast Cancer Subtypes 154
Neoadjuvant chemotherapy for patients with muscle-invasive urothelial bladder cancer candidates for curative surgery: A prospective clinical trial based on cisplatin feasibility 151
191P Radiotherapy (RT) in oligoprogressive metastatic breast cancer (mBC): A retrospective analysis 151
Let‐7a‐5p, mir‐100‐5p, mir‐101‐3p, and mir‐199a‐3p hyperexpression as potential predictive biomarkers in early breast cancer patients 149
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies 147
Palbociclib plus fulvestrant or everolimus plus exemestane for pretreated advanced breast cancer with lobular histotype in er+/her2− patients: A propensity score-matched analysis of a multicenter retrospective patient series 146
ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas 146
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases 146
An Innovative Scoring System to Select the Optimal Surgery in Breast Cancer after Neoadjuvant Chemotherapy 142
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation 142
Radiotherapy benefit in oligoprogressive breast cancer: A retrospective analysis 140
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 140
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy 139
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 135
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 133
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial 129
Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting 128
Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2 127
Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analisys 124
Role of radiomics in predicting early disease recurrence in locally advanced breast cancer patients: integration of radiomic features and RECIST criteria 123
Paradox CA 15-3 increase in metastatic breast cancer patients treated with everolimus: A change of paradigm in a case series 123
Characteristics and risk factors for SARS-CoV-2 in children tested in the early phase of the pandemic: a cross-sectional study, Italy, 23 February to 24 May 2020 123
OlympiAD trial: moving to a next level of treatment for patients with BRCA mutation and her2-negative metastatic breast cancer 122
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer 121
Usefulness of automated breast volume scanner (ABVS) for monitoring tumor response to neoadjuvant treatment in breast cancer patients: preliminary results 120
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives 120
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials 117
Targeted Therapy in Advanced Gastric Carcinoma:the Future is Beginning 117
Menopausal hormone therapy: What should be kept in mind for a personalized choice in a shared decision-making 117
Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors 117
Long-Term Safety of Level II Oncoplastic Surgery after Neoadjuvant Treatment for Locally Advanced Breast Cancer: A 20-Year Experience 116
Diffuse liver infiltration by lobular breast carcinoma: Shear wave elastography as gold standard imaging study. 116
Prognostic Factors in Patients with Breast Cancer Liver Metastases Undergoing Liver Resection: Systematic Review and Meta-Analysis 116
PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives 114
Baseline 18F-FDG PET/CT for predicting pathological response to neoadjuvant chemotherapy and prognosis in locally advanced breast cancer patients: analysis of tumor and lymphoid organs metabolic parameters 114
Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response 114
Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study 112
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer 107
Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis 106
Simultaneous integrated boost intensity-modulated radiotherapy for treatment of bone metastases: analysis of a breast cancer cohort 106
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 105
Lung adenocarcinoma presenting as a solitary gingival metastasis: a case report 104
LUX-Lung 7: is there enough data for a final conclusion? 101
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study 100
Neoadjuvant Chemotherapy in Breast Cancer: An Advanced Personalized Multidisciplinary Prehabilitation Model (APMP-M) to Optimize Outcomes 98
Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analysis 97
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope 97
Level II Oncoplastic Surgery as an Alternative Option to Mastectomy with Immediate Breast Reconstruction in the Neoadjuvant Setting: A Multidisciplinary Single Center Experience 97
Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA 96
Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy 96
Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors 95
From controversy to clarity: reimagining the role of CDK4/6 inhibitors in the adjuvant setting– a number needed to treat perspective 93
How will artificial intelligence impact breast cancer research efficiency? 92
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 90
Treatment of locally advanced gastric cancer (LAGC): Back to lauren’s classification in pan– cancer analysis era? 90
Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study 88
Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians 85
The interference between oxaliplatin & anti-EGFR therapies: A different hypothesis to explain the 'unexplainable' 85
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse 83
The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature 81
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study 76
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC 76
Demystifying BRAF Mutation Status in Colorectal Liver Metastases: A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions 76
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 75
Definition of a tool to assess shared decision-making (SDM) on women with breast cancer: A value-based approach 74
Targeted therapy in advanced gastric carcinoma: The future is beginning 74
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth 74
The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer 71
New life for retrospective study in the precision oncology era 68
Automated breast volume scanner (ABVS) compared to handheld ultrasound (HHUS) and contrast-enhanced magnetic resonance imaging (CE-MRI) in the early assessment of breast cancer during neoadjuvant chemotherapy: an emerging role to monitoring tumor response? 66
New challenges in multimodal workout of locally advanced breast cancer 63
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors 62
Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence 60
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial 59
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 55
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study 52
To treat or no to treat: HER2 equivocal is the matter! 50
Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line 49
Racial and ethnic disparities in breast cancer survival: critical appraisal of the data emerging from the randomized TAILORx 43
BRAF in metastatic colorectal cancer: the future starts now 22
Totale 12.201
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.070
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.070
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022657 59 11 10 67 18 50 18 83 34 41 131 135
2022/20231.395 188 194 99 197 79 142 90 135 145 40 52 34
2023/2024748 40 164 30 34 38 151 53 43 16 19 75 85
2024/20252.005 37 28 135 59 134 51 69 57 203 312 540 380
2025/20266.044 738 265 428 901 867 255 1.027 273 375 409 272 234
2026/202750 50 0 0 0 0 0 0 0 0 0 0 0
Totale 12.224